Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | IKBKB | O14920 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279926 | 0.83 | SCN9A (0.54) | HPGDSMN1; SMN2SCN9ANPC1RAB9A | |
| SCHEMBL17886781 | 0.81 | SCN9A (0.57) | HPGDSMN1; SMN2SCN9ANPC1RAB9A | |
| SCHEMBL3036514 | 0.80 | SCN9A (0.54) | SCN9AIKBKB | |
| SCHEMBL31188482 | 0.80 | ADRB1 (0.60) | HPGDSCN9AIKBKB | |
| SCHEMBL5088410 | 0.80 | ADRB1 (0.60) | HPGDSCN9AIKBKB | |
| SCHEMBL8274391 | 0.80 | ADRB1 (0.60) | HPGDSCN9AIKBKB | |
| SCHEMBL13766453 | 0.80 | SCN9A (0.56) | SCN9AIKBKB | |
| SCHEMBL17816494 | 0.79 | CYP1A2 (0.73) | HPGDSMN1; SMN2SCN9ARAB9ANPSR1 | |
| SCHEMBL17888386 | 0.79 | SCN9A (0.58) | HPGDSMN1; SMN2SCN9ANPC1RAB9A | |
| SCHEMBL1995036 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | HPGD 1195/4885SMN1; SMN2 2456/4885SCN9A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.